Johns Hopkins Bloomberg School of Public Health

Patients Who Had More Severe Covid-19 May Be the Best Donors for Convalescent Plasma Therapy

Study links stronger antibody responses to more severe disease, as well as more advanced age and male sex

Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease, according to a new study co-led by researchers at Johns Hopkins Bloomberg School of Public Health.

The findings suggest that older males who have recovered from COVID-19 after having been hospitalized are strong candidates for donating plasma for treating COVID-19 patients. Doctors have been using infusions of plasma—the part of blood that contains antibodies—from recovered COVID-19 patients to treat COVID-19 patients and also as a possible prophylaxis to prevent COVID-19.

Doctors have used convalescent plasma to treat patients or immunize persons at high risk of virus exposure during outbreaks of measles, mumps, polio, Ebola, and even the 1918 pandemic flu.

Clinical trials of convalescent plasma treatment against COVID-19 are ongoing, and doctors until now haven’t had guidance for selecting COVID-19 survivors who are likeliest to have strong antibody responses.

“We propose that sex, age, and severity of disease should be used to guide the selection of donors for convalescent plasma transfer studies because we found that these were significant patient characteristics that not only predicted the amount of antibody but the quality of that antibody,” says study lead author Sabra Klein, PhD, professor in the Bloomberg School’s Department of Molecular Microbiology and Immunology.

The study, published October 19 in the Journal of Clinical Investigation, was a collaboration with several other research groups including that of Arturo Casadevall, MD, PhD, Bloomberg Distinguished Professor and chair of the Department of Molecular Microbiology and Immunology, and co-corresponding author Aaron Tobian, MD, PhD, professor in the Department of Pathology and director of the Transfusion Medicine Division at the Johns Hopkins School of Medicine.

For their study, the researchers tested the blood of 126 COVID-19 survivors and found high variability in their antibody levels and their antibodies’ ability to neutralize the COVID-19-causing coronavirus, SARS-CoV-2. Three factors were associated with stronger antibody responses: having been sick enough with COVID-19 to be hospitalized, being older, and being male.

Initial studies of recovered COVID-19 patients have revealed a significant variability in their antibody responses to the virus—some survivors having very weak responses that would almost certainly be ineffective in helping new patients. The researchers in the new study looked for factors that might help explain some of that variability and guide clinicians to the patients most likely to have high levels of SARS-CoV-2 neutralizing antibodies.

The researchers examined samples of plasma from the 126 recovered patients using several tests. These included tests of the plasma’s ability in cell cultures to neutralize cell-to-cell infection with SARS-CoV-2, as well as commercial tests for levels of antibodies to the coronavirus’s spike protein—the protein that studs the surface of coronavirus particles and allows the virus to attach to and infiltrate human cells.

Consistent with several prior studies, the researchers found considerable variability among the subjects in their spike-protein antibody levels and plasma coronavirus-neutralization potency. But on average, the plasma of survivors who had been hospitalized with COVID-19 had markedly more anti-spike protein antibodies and neutralized the virus more effectively—suggesting that disease severity prompts a stronger immune response.

“We know that the magnitude of antibody responses correlates with disease severity in other infectious diseases, such as active tuberculosis,” Klein says.

Older age and male sex, which prior studies in both China and Europe have shown are associated with more severe COVID-19, were also associated with stronger antibody responses, though these links were weaker than for hospitalization status.

As part of their study, the researchers also tested study participants with commercial test kits and found that recovered COVID-19 patients who have strong neutralizing antibody responses also are very likely to have high levels of coronavirus anti-spike antibodies. This suggests that this type of test kit, which is relatively inexpensive, might be a good tool for identifying suitable plasma donors for clinical trials and treatments.

“Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population,” was funded by the National Institutes of Health (U54AG062333, HHSN272201400007C, T32A1007417, AI052733, AI15207, R01AI120938, R01AI120938S1, R01AI128779, 1K23HL151826-01, R01HL059842), Bloomberg Philanthropies, and the Department of Defense (W911QY2090012).

# # #

MEDIA CONTACT
Register for reporter access to contact details
CITATIONS

National Institutes of Health (U54AG062333, HHSN272201400007C, T32A1007417, AI052733, AI15207, R01AI120938, R01AI120938S1, R01AI128779, 1K23HL151826-01, R01HL059842); the Department of Defense (W911QY2090012); Journal of Clinical Investigation, Oct 2020




Filters close

Showing results

110 of 4156
Newswise: Stimulus Relief Funds Increase Social Distancing to Stop Spread of COVID-19
23-Nov-2020 5:20 PM EST
Stimulus Relief Funds Increase Social Distancing to Stop Spread of COVID-19
University of California San Diego

As case rates of COVID-19 reach new heights across the nation, many states and cities are tightening stay-at-home restrictions to stop the spread. New research suggests that that those suffering from economic hardships are less likely comply with new stay-at-home orders; however these same U.S. residents would be more likely to adhere to the new public health guidelines if their households received stimulus funds.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 9:15 AM EST Released to reporters: 30-Nov-2020 2:30 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 9:15 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded covid-19-update-surge-preparedness-vaccine-distribution
VIDEO
Released: 30-Nov-2020 2:20 PM EST
COVID-19 Update: Surge Preparedness, Vaccine Distribution
Cedars-Sinai

With the novel coronavirus spreading across the U.S. at a record pace, Cedars-Sinai has been seeing an increase in COVID-19 patients at its hospitals and through its network of physicians. But the health system's leaders say Cedars-Sinai is prepared.

Released: 30-Nov-2020 1:20 PM EST
Rethink COVID-19 infection control to keep primary schools open this winter, governments urged
BMJ

An urgent rethink of infection control policies to keep COVID-19 infection at bay in schools is needed if primary schools are to be kept open this winter, and the knock-on effects on their families avoided, argue children's infectious disease specialists in a viewpoint, published online in the Archives of Disease in Childhood.

Newswise: Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Released: 30-Nov-2020 12:45 PM EST
Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Hackensack Meridian Health

Don’t Delay Your Care – Our dnhanced pandemic safety precautions prioritize patient health and allow providers to deliver outstanding in-office, telehealth and surgical care

Released: 30-Nov-2020 12:10 PM EST
Struggles of care home staff during COVID-19 first wave revealed in Whatsapp messages
University of Leeds

Analysis of social media messages between care home staff on the coronavirus front line reveal their growing concerns over how to manage in the face of the virus.

Released: 30-Nov-2020 11:30 AM EST
More than one-third of children with COVID-19 show no symptoms: study
University of Alberta Faculty of Medicine & Dentistry

More than one-third of kids who have COVID-19 are asymptomatic, according to a University of Alberta study that suggests youngsters diagnosed with the disease may represent just a fraction of those infected.

Newswise: Promising lab results in quest to find naturally occurring anti-COVID therapies
24-Nov-2020 5:35 PM EST
Promising lab results in quest to find naturally occurring anti-COVID therapies
University of Alabama Huntsville

So far, 35 of 125 naturally occurring compounds identified computationally at The University of Alabama in Huntsville (UAH) to have potential against COVID-19 have shown efficacy in ongoing first-batch testing at the University of Tennessee Health Science Center’s Regional Biocontainment Laboratory (UTHSC RBL) that’s the next step in the process to becoming a drug.

Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.


Showing results

110 of 4156

close
2.52751